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Abstract 32 
Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1 33 
T cell checkpoint induces T cell infiltration and anti-cancer responses in murine and human 34 
pancreatic cancer. Here we elucidate the mechanism by which CXCR4 inhibition effects the 35 
tumor immune microenvironment. In human immune cell-based chemotaxis assays, we find that 36 
CXCL12-stimulated CXCR4 inhibits the directed migration mediated by CXCR1, CXCR3, 37 
CXCR5, CXCR6, and CCR2, respectively, chemokine receptors expressed by all the immune 38 
cell types that participate in an integrated immune responses. Inhibiting CXCR4 in an 39 
experimental cancer medicine study by one-week continuous infusion of the small molecule 40 
inhibitor, AMD3100 (plerixafor), induces an integrated immune response that is detected by 41 
transcriptional analysis of paired biopsies of metastases from patients with microsatellite stable 42 
colorectal and pancreatic cancer. This integrated immune response occurs in three other 43 
examples of immune-mediated damage to non-infected tissues: rejecting renal allografts, 44 
melanomas clinically responding to anti-PD1 antibody therapy, and microsatellite instable 45 
colorectal cancers. Thus, signaling by CXCR4 causes immune suppression in human PDA and 46 
CRC by impairing the function of the chemokine receptors that mediate the intratumoral 47 
accumulation of immune cells.  48 
 49 
Statement of significance 50 
Continuous infusion of AMD3100, an antagonist of the chemokine receptor, CXCR4, induces an 51 
integrated anti-cancer immune response in metastases of patients with microsatellite stable 52 
pancreatic and colorectal cancer that is predictive of response to T cell checkpoint inhibition.  53 
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Introduction 54 
T cell checkpoint antagonists that target the regulatory membrane proteins on T cells, CTLA-4 55 
and PD-1, have demonstrated the therapeutic potential of the immune system in cancer. Clinical 56 
responses, however, have been limited to subsets of patients with certain cancers (1–4). Lack of 57 
cancer cell antigenicity (5), dysfunction of cytotoxic CD8+ T cells (6), and systemic immune 58 
modulation (7,8) have been some of the potential explanations for resistance of these cancers to 59 
T cell checkpoint inhibitors.  A more general immunological principle in which mesenchymal 60 
cells may control the immune response to immunogenic epithelial tissues should also be 61 
considered (9). 62 
 63 
The presence of tertiary lymphoid structures (TLSs) in human adenocarcinomas correlates with 64 
better long-term clinical outcome and clinical response to T cell-checkpoint inhibitors (10–13), 65 
suggesting that organized intratumoral lymphoid structures promote anti-tumor immune 66 
reactions.  Mesenchymal stromal cells organize B and T cells in both secondary and tertiary 67 
lymphoid structures mainly by producing chemokines: CCL19 and CCL21 from fibroblastic 68 
reticular cells (FRCs) recruit CCR7-expressing lymphocytes and dendritic cells (DCs), and 69 
CXCL13 from follicular dendritic cells (FDCs) attracts CXCR5-expressing T and B cells (14).  70 
Notably, these two stromal cell types develop from an embryonic precursor that expresses the 71 
membrane protein, Fibroblast Activation Protein- a (FAP), and may be developmentally related 72 
to the FAP-expressing fibroblastic stromal cell type that resides in solid tumors, which is termed 73 
the cancer-associated fibroblast (CAF) (15–18).  CAFs also affect the trafficking of lymphocytes 74 
by producing a chemokine, CXCL12 (19), but in a manner that opposes the effects of lymphoid 75 
tissue stromal cells, by suppressing the intra-tumoral accumulation of T cells (20). Indeed, 76 
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continuous inhibition of CXCR4 in a mouse model of pancreatic cancer leads to T cell 77 
infiltration of the tumors and results in response to anti-PD-L1 antibody administration (20). 78 
Therefore, whether the tumor stroma supports or suppresses immune activation may depend on 79 
the relative contributions of these related stromal cell types.  A pre-dominance of CAFs would 80 
suppress local immunity, whereas the presence of FRCs and FDCs and the development of TLSs 81 
would enhance intratumoral immunity.  This concept has been supported by pre-clinical studies 82 
in which immune control of tumor growth in mice occurred after FAP+ CAFs were conditionally 83 
depleted (18,20). 84 
 85 
Here we report the results from a proof of concept experimental medicine study in which we 86 
tested the immunological consequences of inhibiting CXCR4 in patients with cancers that have 87 
historically resisted immunotherapy, micro-satellite stable (MSS) colorectal cancer (CRC) or 88 
pancreatic ductal adenocarcinoma (PDA).  We report that continuous administration for one 89 
week of AMD3100 (plerixafor, MozobilTM), a small molecule inhibitor of CXCR4, promotes an 90 
integrated immune response in metastatic lesions from these patients. 91 
 92 
Results 93 
Colorectal and pancreatic cancer cells display a CXCL12 “coat” 94 
In murine PDA tumors, cancer cells display a “coat” of CXCL12, the chemokine that FAP+ 95 
CAFs produce to mediate their immune suppressive activity (20). We assessed whether such a 96 
CXCL12-coat is displayed on human PDA or CRC cancer cells by examining tumor tissue 97 
microarrays.  Fluorescently labeled anti-CXCL12 antibodies stained the KRT19-expressing 98 
cancer cells in formalin fixed paraffin embedded (FFPE) tissue sections of human PDA and CRC 99 
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(Fig. 1).  100 
 101 
CXCL12 stimulated CXCR4 inhibits the directed migration of human immune cells mediated by 102 
chemokine receptors  103 
We assessed whether CXCL12 stimulation of CXCR4 altered the trafficking of human immune 104 
cells by performing in vitro transwell migration assays using Boyden chambers. We generated 105 
human cell lines that co-expressed CXCR4 with the chemokine receptors that mediate the 106 
directed migration of innate and adaptive immune cells: CXCR1 in Jurkat-CXCR4/CXCR1 cells, 107 
CXCR3 in HSB2DP-CXCR4/CXCR3 cells, CXCR5 in Raji-CXCR4/CXCR5 cells, CXCR6 in 108 
Jurkat-CXCR4/CXCR6 cells, and CCR2 in Molm13-CXCR4/CCR2 cells, respectively (Fig. 2 109 
and Fig. S1). These chemokine receptors and their respective chemokines mediate the directed 110 
migration of neutrophils (CXCR1; CXCL8), T cells, dendritic cells, and NK cells (CXCR3; 111 
CXCL9 and CXCL10), B cells (CXCR5; CXCL13), tissue-resident memory T cells (CXCR6; 112 
CXCL16), and monocytes and macrophages (CCR2; CCL2) (Fig. 2).  Including CXCL12 in the 113 
upper chamber of the Boyden two chamber assay inhibited the migration of the human immune 114 
cells co-expressing CXCR4 with each one of the five other chemokine receptors towards its 115 
relevant chemokine in the lower chamber.  The inhibition was dependent on CXCR4 expression 116 
(Fig. S1) and was unidirectional, in that stimulating the relevant immune cell lines with their 117 
respective chemokines for CXCR1, CXCR3, CXCR5, CXCR6 or CCR2 did not abolish the 118 
CXCR4-mediated chemotactic response to CXCL12 (Fig. 2). Incubating HSB2DP-119 
CXCR4/CXCR3 cells with CXCL12 followed by removal of the chemokine restored the ability 120 
of cells to migrate in response to a CXCL10 gradient (Fig. S2). 121 
 122 
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AMD3100 suppresses CXCL12-stimulated inhibition of other chemokine receptors 123 
In previous murine studies a continuous plasma concentration of 2 µg/ml (4 µM) AMD3100 124 
unmasked anti-PDA immunity and led to reduced tumor growth rates and synergy with anti-PD-125 
L1 treatment (20). We thus examined the effect of AMD3100 in chemotaxis studies across this 126 
range of drug concentration in these human cell lines. AMD3100 fully inhibited the CXCR4-127 
mediated chemotactic responses of all immune cell lines (Fig. 3).  The CXCR4 inhibitor also 128 
fully reversed the inhibition by CXCL12 of the chemotactic functions of CXCR1 and CXCR6 on 129 
the CXCR4-expressing Jurkat cells (Fig. 3).  The functions of CXCR3, CXCR5 and CCR2 were 130 
only partially restored, which correlated with the inhibitory effects of AMD3100 on CXCR3-, 131 
CXCR5-, and CCR2- mediated chemotaxis in the absence of CXCL12 (Fig. S3).  This inhibitory 132 
effect of AMD3100 may be caused by partial agonism of CXCR4, which has been reported (21). 133 
Since CXCR1, CXCR3, CXCR5, CXCR6 and CCR2 mediate the trafficking of neutrophils, T 134 
cells, NK cells, DCs, B cells, tissue-resident memory T cells and monocytes, these observations 135 
suggest that AMD3100 may alter the trafficking of multiple immune cell types within tumors, 136 
thereby inducing an integrated immune response to the cancer cells. We tested this hypothesis in 137 
an experimental medicine study.  138 
 139 
Experimental medicine study of continuous AMD3100 infusion: Study design, recruitment and 140 
patient characteristics 141 
We targeted the CXCL12/CXCR4 interaction using AMD3100 in an experimental medicine 142 
study of the immunological role of CXCR4 signaling in patients with MSS CRC and MSS PDA 143 
(NCT02179970). AMD3100 has a plasma half-life of approximately 8 hours.  To achieve 144 
continuous inhibition of CXCR4, as has been recommended for other chemokine receptors (22), 145 
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AMD3100 was delivered by continuous intravenous infusion for 7 days with the target steady-146 
state plasma concentration being approximately 2 µg/ml (4µM). We assessed the 147 
pharmacokinetics, pharmacodynamics, and intratumoral immunological changes during 148 
treatment using serial blood tests, clinical imaging modalities, and investigations from paired 149 
biopsies taken prior to and at the end of the AMD3100 infusion (Fig. S4 and Fig. S5A).  150 
 151 
We enrolled 26 patients at two centers, 24 at the Cambridge University Hospitals NHS 152 
Foundation Trust and two at Weill Cornell Medicine/New York Presbyterian Hospital. The 153 
patient eligibility criteria are shown in the Materials and Methods section. The characteristics of 154 
all enrolled patients are summarized in Table 1. On histopathological review, one patient was 155 
found to have predominantly neuroendocrine cancer cells in the biopsy tissue and this patient 156 
was therefore excluded from all analyses other than the safety and pharmacokinetic analysis. The 157 
remaining 25 patients had treatment-refractory, histologically confirmed MSS PDA (n=10) or 158 
MSS CRC (n=15). An important inclusion criterion was the presence of a baseline lymphocyte 159 
count above the lower limit of normal (1.0 x 109/L) at screening, because of concerns relating to 160 
adequate immune status and resolution of immunosuppression after previous chemotherapy.  161 
Twenty-four patients with CRC or PDA were treated with AMD3100 (one registered patient did 162 
not commence study drug, because of a disease related adverse event (AE)):  17 in the dose 163 
escalation phase (two, PDA; 15, CRC) and seven further patients with PDA in the dose 164 
expansion phase. We confirmed the presence of the CXCL12-coat in all patients enrolled in the 165 
dose escalation phase who had evaluable tissue (Fig. S6). 166 
  167 
Pharmacokinetic and toxicity results 168 
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 9 
The first dose level of AMD3100 was an iv infusion at a rate of 20 µg/kg/hr, with subsequent 169 
patients enrolled at dose cohorts of 40, 80, and 120 µg/kg/hr, using a 3+3 design.  There were no 170 
Dose Limiting Toxicities (DLTs) identified in the 20, 40 and 80 µg/kg/hr dose cohorts, but 2 171 
patients experienced DLTs at the 120µg/kg/hr dose (Table S1). One patient had a vasovagal 172 
reaction (grade 3) in the context of pain shortly after the Day 8 biopsy and prior to completion of 173 
the AMD3100 infusion. One patient who had peritoneal disease developed severe abdominal 174 
pain (grade 3), hypotension (grade 3), and a vasovagal reaction (grade 3) on day 2 of the 175 
infusion.  Symptoms resolved within 24 hr after discontinuing the drug, medications for pain 176 
control, and IV fluids. Continuous infusion of AMD3100 has been reported to be associated with 177 
vasovagal reactions (23), and these events were classified as DLTs. A complete list of graded 178 
AEs is included in the supplemental material (Table S2). 179 
 180 
In the trial of continuous IV infusion of AMD3100 for one week in 40 patients with HIV, a 181 
single patient experienced premature ventricular contractions (23).  Thus, in the current study, all 182 
patients were admitted for the initial 72 hrs of the AMD3100 infusion for continuous cardiac 183 
telemetry monitoring, and Holter monitoring thereafter.  No cardiac rhythm disturbances were 184 
identified at the 80  g/kg/hr infusion rate chosen for the expansion phase.  Minor changes 185 
(Table S2) were only possibly drug related, and there were no cardiac AEs that required drug 186 
interruption and all resolved without sequelae. Therefore, hospital-based telemetry is not 187 
indicated in future studies using this infusion protocol and static ECGs and ambulatory Holter 188 
monitoring should provide sufficient cardiac monitoring. 189 
 190 
The dose rate of 80 µg/kg/hr yielded the target plasma level of ~2 µg/ml (4µM), and was chosen 191 
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for the expansion cohort which resulted in a mean steady state plasma concentration of 2.3 µg/ml 192 
(SD ± 0.9 µg/ml) AMD3100 in patients enrolled at this dose rate (Fig. S5B, Table S3). This 193 
infusion rate was overall well tolerated (Table S2). 194 
 195 
Pharmacodynamic and clinical results 196 
In accordance with the well characterized biological role of CXCL12/CXCR4 ligation for the 197 
retention of hematopoietic stem cells and immature leukocytes in the bone marrow (24), CD34+ 198 
and other leukocyte populations were elevated during the period of AMD3100 infusion.  These 199 
changes had almost completely resolved by day 28 of the study, 20 days after discontinuation of 200 
the infusion (Fig. S7). By conventional CT scanning on day 20-24, no complete or partial 201 
responses were identified in 23 evaluable patients.   Thirteen patients (57%) had stable disease 202 
and 10 (43%) disease progression. Paired PET-CT scans were evaluable in 19 participants (12 203 
escalation phase, 7 expansion phase).  Of these, 11 participants had CRC and 8 PDA.  Clinically 204 
significant (defined as delta Standardized Uptake Values mean weighted average (SUV MWA) ≥ 205 
30%) changes were seen in 2 participants.  Both were patients with CRC (treated at 40 µg/kg/hr) 206 
and had a ≥30% increase in SUV MWA (71% and 32%). 207 
 208 
Immunological analysis of metastatic tissue from pre-treatment and on-treatment biopsies 209 
We performed immunological analyses on all patients who had sufficient sample material for 210 
comparative histopathological and RNA studies (PDA n=4; CRC n=10) (Fig. S4). We first 211 
sought histological evidence of an immunological response to CXCR4 inhibition by determining 212 
the frequency of CD8+ T cells in paired pre- and end-of-treatment biopsies of metastatic lesions. 213 
FFPE tissue sections were stained with antibodies specific for CD8a and keratin (pan-CK), 214 
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respectively (Fig. 4A).  There was a significant increase in the number CD8+ T cells in the pan-215 
CK+ cancer cell areas after treatment with AMD3100 (Fig. S8A). Frozen samples of different 216 
biopsy passes of the same metastatic lesions were subjected to bulk RNA-Seq analysis.  The 217 
CD8a mRNA levels were significantly upregulated after AMD3100 administration (Fig. S8B), 218 
and significantly correlated with the histopathologically determined CD8+ T cell frequencies 219 
(Fig. 4B).  This validation of the quantitative RNA-Seq transcriptomic set justified the further 220 
analysis of this comprehensive source of immunological data.  221 
 222 
By enrichment analysis of the RNA-Seq data, we found that continuous inhibition of CXCR4 by 223 
infusion of AMD3100 induced intra-tumoral T and NK cell accumulation and activation (Fig. 224 
4C) and also induced an activated B cell response. Eighteen of the 100 most differentially 225 
expressed genes were derived from the B cell lineage. The upregulated expression of transcripts 226 
encoding the J chain, heavy chain constant regions, and TNFRSF17, when taken together with 227 
the more modest increased expression of MS4A1 (CD20), CD19, TNFRSF13B and 228 
TNFRSF13C suggests that this response is more a consequence of plasma cell differentiation 229 
than an accumulation of B cells (Table S4).  A plasma cell transcriptional signature in breast and 230 
lung adenocarcinomas has been shown to correlate with improved survival (25).  This 231 
AMD3100-induced T and B cell response was accompanied by transcriptional evidence for the 232 
development of TLSs (Fig. 4D and E, Table S4).  The restriction of CCL19 mRNA, which is 233 
expressed only by FRCs (26), to tumor stromal cells that were FAP+, a marker not only of CAFs 234 
but also of FRCs (15,27), was demonstrated by fluorescent in situ hybridization (FISH). The 235 
FAP+ cells expressing CCL19 increased significantly from 5.8% to 25.7% (Fig. 4D), suggesting 236 
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either that CAFs were differentiating to FRCs within the tumor microenvironment, or that FRCs 237 
were being recruited from a source outside the tumors.  238 
 239 
The INTegrated Immune REsponse (INTIRE) and immune-mediated damage to non-infected 240 
tissues 241 
The similarity of the AMD3100-induced transcriptional changes to those that characterize 242 
tumors with TLSs (Fig. 4E), micro-satellite instable (MSI) CRC (Fig. 4F), and rejecting renal 243 
allografts (Fig. 4G) suggested that the inhibition of a single chemokine receptor, CXCR4, may 244 
induce an integrated immune reaction that is characteristic of non-infected, immunogenic tissues. 245 
To assess the integrated immune response, we developed the INTIRE gene signature which was 246 
defined by 194 genes that together identify nine components of innate and adaptive immunity 247 
(Table S5): Monocyte/Macrophage/DC/Antigen Presentation, T and NK Cell Accumulation, T 248 
and NK Effector Cells, Chemokines and Chemokine Receptors, Activated B Cells (Germinal 249 
Center B Cells) and Plasma Cells, Stromal/FRC/TLS, Type I/III Interferon Response, and 250 
Endothelial Cells (blood and lymphatic). AMD3100 treatment of MSS PDA and MSS CRC 251 
patients induced the INTIRE gene signature (Fig. 5A).  Upregulation of the INTIRE gene panel 252 
also was associated with decreased expression of E2F target genes and other genes involved in 253 
the G2M checkpoint, possibly indicating a reduction in replicating cancer cells in the tumor. The 254 
INTIRE gene signature also distinguished between rejecting and non-rejecting renal allografts in 255 
two studies (28,29), a prototypical example of immunologically mediated damage to non-256 
infected tissue. Relative to MSS CRC, MSI CRC demonstrated the INTIRE gene signature (Fig. 257 
5A) (30,31), but, in contrast to the effects of inhibiting CXCR4 in MSS CRC and MSS PDA, 258 
MSI CRC did not exhibit decreased Cell Cycle gene expression (Fig. 5A). The INTIRE gene 259 
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signature was also present in tumors from longer surviving patients in the data from the 260 
PREdiction of Clinical Outcomes from Genomic Profiles (PRECOG) study (Fig. 5B) (25).  In 261 
two studies of melanoma patients treated with anti-PD-1 antibody after 28 days and 11 days, 262 
respectively (32,33), and a study of melanoma patients treated with combination anti-PD-1 plus 263 
anti-CTLA-4 antibodies (33), responders demonstrated the INTIRE gene signature.  Remarkably, 264 
the INTIRE gene signature also distinguished between melanomas that subsequently responded 265 
to treatment with anti-PD-1 antibody from those that did not (32,33) (Fig. 5A and C).  Finally, 266 
melanomas in patients who were depleted of B cells by administration or anti-CD20 (34) 267 
demonstrated an attenuated INTIRE gene signature (Fig. 5A and D), exemplifying the integrated 268 
nature of this immune response.  269 
 270 
Immune-mediated anti-cancer effects of AMD3100 administration 271 
We examined the transcriptional changes in the paired biopsies for evidence of intratumoral 272 
immune mediated anti-cancer effects. Changes in the mRNA levels in biopsies from each patient 273 
of granzymes (GZM) A, B, H, K, and M and perforin, which encode the proteins that mediate 274 
killing by effector CD8+ T cells, significantly inversely correlated with changes in the mRNA 275 
levels of three genes uniquely expressed by cancer cells, CEACAM 5, 6, and 7 (Fig. 6A), but not 276 
with non-cancer-specific genes (Fig. S9).  277 
 278 
Next we evaluated plasma biomarker evidence of anti-cancer effects in all samples that passed 279 
the respective quality thresholds for analysis. The plasma concentrations of the tumor-derived 280 
markers, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (Ca19-9), which are 281 
not validated as early response markers in immunotherapy trials, were not significantly changed 282 
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over the 7 day treatment period of the patients with AMD3100 (n=15, p=0.4). Next, we 283 
quantified circulating tumour DNA (ctDNA). Levels of ctDNA have been shown to decrease 284 
when patients respond to therapy (35–38). We evaluated ctDNA levels at baseline and after 7 285 
days of treatment with AMD3100 (Fig. 6B). ctDNA levels were significantly reduced following 286 
treatment with AMD3100 (n=15, p=0.033). Furthermore, plasma levels of CXCL8, which has 287 
also been identified as a marker of tumour burden (39) and may provide an early indicator of 288 
therapeutic response (39–41), were also significantly decreased following treatment with 289 
AMD3100 (Fig. 6C, n=18, p<0.0001). The decrease in both ctDNA and CXCL8 levels support 290 
the possibility of an early anti-cancer effect mediated by CXCR4 inhibition.  291 
 292 
Discussion 293 
The findings that the CAF mediates intratumoral immune suppression (18,20) and that a CAF-294 
derived chemokine, CXCL12, coats the cancer cells in PDA and CRC suggest that its receptor, 295 
CXCR4, has a role in mediating immune suppression in the tumor microenvironment.  The 296 
association of CXCL12 with cancer cells is predicted to have two immunological consequences.  297 
First, most immune cells in PDA and CRC tumors express CXCR4 and will, therefore, be 298 
stimulated by cancer cell-associated CXCL12 via ligation of this receptor.  Second, CXCL12-299 
stimulated CXCR4 inhibits the chemotactic functions of the chemokine receptors that direct the 300 
migration of immune cells. Therefore, the CXCL12-coat of cancer cells could impair the intra-301 
tumoral accumulation of multiple immune cell types. We tested these two predictions in an 302 
experimental medicine study in which patients with PDA and CRC received the, small molecule 303 
CXCR4 antagonist, AMD3100, which is licensed for mobilization of hematopoietic stem cells. 304 
 305 
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Treatment of patients with AMD3100 was limited to continuous iv infusion of the drug for one-306 
week, using a protocol shown to be safe in patients with HIV (23).  We first confirmed that the 307 
AMD3100 infusion did achieve continuous CXCR4 inhibition by observing the presence of 308 
CD34+ HSCs in the peripheral blood of each patient.  All patients from the dose escalation phase 309 
showed persistent elevations of CD34+ HSCs, indicating the occurrence of continuous CXCR4 310 
inhibition, and we therefore included patients from the entire cohort in all subsequent analyses.  311 
The short duration of drug administration  limited our ability to observe whether CXCR4 312 
inhibition induced clinical responses in patients with PDA or CRC, as assessed by standard 313 
radiological evaluations (42,43).  These assessments did not reveal remissions and the lack of 314 
change in tumor volume is not informative due to the short time period that elapsed between 315 
scans. An independent clinical trial testing discontinuous CXCR4 inhibition by subcutaneous 316 
administration of a cyclic peptide inhibitor of CXCR4 together with anti-PD-1 antibody over 317 
several cycles in patients with advanced pancreatic cancer showed some evidence of clinical 318 
responses (44). We observed significant decreases in the levels of ctDNA and circulating 319 
CXCL8 of patients after treatment with AMD3100.  ctDNA and CXCL8 are increasingly 320 
recognized as markers of tumour burden (35,38,39) and may provide early indications of 321 
response to therapy (35–41), when imaging evaluation is not conclusive (42,43). However, these 322 
intial observations will require further prospective validation.  323 
 324 
This study focused on the question of whether the CXCL12-coating of cancer cells in PDA and 325 
CRC signified the existence of a fundamental immune suppressive pathway in two human 326 
cancers that have thus far resisted cancer immunotherapy. We chose to detect immunological 327 
changes by performing bulk RNASeq analysis of paired biopsies of metastatic lesions taken from 328 
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patients before and at the end of the AMD3100 infusion.  This analysis provided an unbiased and 329 
quantitative means of measuring the AMD3100-induced changes in the complex intratumoral 330 
immune environments of these tumors, which could be compared to similar transcriptional 331 
analyses of tissues representing other immunological reactions. 332 
 333 
This comparative transcriptional analysis revealed unanticipated similarities between the 334 
immunological effects of two mechanistically distinct immunotherapies, inhibition of T cell 335 
checkpoints and inhibition of a chemokine receptor, respectively, in cancers that have different 336 
developmental origins, adenocarcinomas and melanomas.  Both anti-PD-1 and anti-CTLA-4 337 
antibody therapies, which enhance the activation of T cells, and AMD3100 treatment, which 338 
affects the trafficking of immune cells, up-regulated the expression of genes that characterize 339 
rejecting renal allografts, an example of immune damage to immunogenic, non-cancer tissue.  340 
Thus, effective cancer immunotherapy engages an immune pathway that mediates damage to 341 
non-infected, immunogenic tissue.  This pathway involves multiple immune elements, and their 342 
participation could be assessed by the INTIRE signature, which characterizes nine components 343 
of the immune reaction.  This analysis showed that the INTIRE signature was induced not only 344 
by CXCR4 inhibition in patients with PDA and CRC, but also by successful treatment of patients 345 
with melanoma with anti-PD-1 antibody. The occurrence of the INTIRE signature was even 346 
predictive of subsequent clinical responses to anti-PD-1antibody therapy in patients with 347 
melanoma.  The additional finding that AMD3100 leads to the increased frequency of FAP+ 348 
cells expressing CCL19, which is a characteristic of FRCs, is consistent with the concept that 349 
shifting the balance from immune suppressive fibroblastic cells to those with immune-enhancing 350 
functions improves the outcome of cancer immunotherapy. This observation is reminiscent of the 351 
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recent reports that the presence of TLSs, which in the mouse requires FAP+ fibroblasts (15, 45), 352 
correlates with clinical responses to T cell checkpoint therapy (11–13). 353 
 354 
Finally, the study raises the possibility that a substantial proportion of patients with MSS PDA 355 
and MSS CRC have on-going anti-cancer immune responses.  A majority of the patients treated 356 
with AMD3100 showed enhanced intra-tumoral immune B and T cells responses after only 357 
seven days, which would be unusually rapid for a primary immune response.  Thus, intra-358 
tumoral immune suppression rather than immune ignorance may be a major barrier to clinically 359 
effective immunotherapy. This possibility should be assessed with an appropriate clinical trial of 360 
repeat cycles of continuous CXCR4 inhibition in combination with a T cell checkpoint 361 
antagonist.    362 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2020. ; https://doi.org/10.1101/2020.07.08.20129361doi: medRxiv preprint 
 18 
Acknowledgements 363 
We thank all patients. 364 
The study was carried out at/supported by the NIHR Cambridge Clinical Research Facility. 365 
 366 
We acknowledge support from the Human Research Tissue Bank, supported by the NIHR 367 
Cambridge Biomedical Research Centre, for sample processing, and the Histopathology Core 368 
Facility at the CRUK CI for sample immunostaining and imaging. 369 
 370 
We thank Purity Bundi, Breanna Demestichas, Nikos Demiris, Kate Donoghue, Alex Overhill, 371 
Richard Houghton, and Eva Serrao for help with data acquisition, trial management, and data 372 
illustration and Hannah Meyer for critical appraisal of the manuscript.  373 
 374 
Funding: SU2C-Lustgarten Foundation Dream Team.  Cancer Research UK Institute core grants 375 
C14303/A17197 and C9545/A29580.  The Li Ka Shing Centre in which some of this research 376 
was performed was generously funded by CK Hutchison Holdings Limited, the University of 377 
Cambridge, Cancer Research UK, The Atlantic Philanthropies and a range of other donors. 378 
Individual funding acknowledgements:  379 
DIJ, FR: CRUK C14303/A17197 and C9545/A29580 380 
TJ: CRUK C42738/A24868; National Institutes of Health USA 5P30CA045508-31; Pershing 381 
Square Innovation Fund. 382 
CMC: Experimental Medicine Initiative Clinical Lectureship 383 
 384 
  385 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2020. ; https://doi.org/10.1101/2020.07.08.20129361doi: medRxiv preprint 
 19 
Conflict of Interest:  Sanofi provided study drug for the clinical trial and validation of the PK 386 
assay, but had no part in study design, data acquisition, data analysis, or manuscript preparation. 387 
 388 
Current employment: 389 
MS: Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada  390 
LM: AstraZeneca, R&D Oncology, The Anne McLaren Offices, C/O Academy House, Central 391 
Cambridge, 136 Hills Road, Cambridge CB2 0QH. 392 
  393 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2020. ; https://doi.org/10.1101/2020.07.08.20129361doi: medRxiv preprint 
 20 
Methods 394 
Immunofluorescence of human tumor arrays 395 
Formalin fixed, paraffin embedded (FFPE) human pancreatic and colorectal tumor arrays (US 396 
Biomax) were deparaffinized in Xylene, washed three times with ethanol, and rehydrated in a 397 
serial concentration of ethanol (from 95% to 50%) and finally in water. For antigen retrieval, the 398 
sections were boiled in 10 mM Tris, pH 8.8 plus 1 mM EDTA for 10 minutes followed by 399 
cooling down for 30 minutes, a wash with PBS, and blocking with 1% BSA/PBS at room 400 
temperature for 1 hour. Following two washes with 0.05% Tween-20/PBS and one with PBS, 401 
Alexa Fluor 568 conjugated anti-KRT19 antibody (Abcam, ab203445) and FITC conjugated 402 
anti-CXCL12 antibody (R & D Systems, IC350F) were applied and the sections were incubated 403 
at room temperature for 1 hour. Finally, the sections were stained with DAPI (Thermo, R37606) 404 
for 10 minutes and washed with 0.05% Tween-20/PBS for two times and once with PBS, 405 
followed by application of mounting medium (Thermo, P36961) and imaging with Leica SP8 406 
confocal microscope. Images were analyzed and exported through ImageJ. 407 
 408 
Chemotaxis assays 409 
Plasmids 410 
To generate lentiviral plasmid expressing human chemokine receptors, CXCR1 and CXCR3 411 
cDNA from CXCR1-Tango (Addgene, #66259) and CXCR3-Tango (Addgene, #66261), 412 
respectively, were amplified and subcloned into lentiCas9-blast (Addgene, #52962) with 413 
restriction enzymes Age1 and BamH1 to replace SpCas9; CXCR5 and CXCR6 cDNA from 414 
CXCR5-Tango (Addgene, #66263) and CXCR6-Tango (Addgene, #66264), respectively, were 415 
amplified and subcloned into lentiCas9-puro to replace SpCas9 where blasticidin resistant gene 416 
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(blast) was also replaced with puromycin resistant gene (puro). For CRISPR editing, control 417 
guide (sgScramble, GCTTAGTTACGCGTGGACGA) and guides targeting to human CXCR4 418 
gene (sgCXCR4-1, TGACATGGACTGCCTTGCAT; sgCXCR4-2, 419 
CAACCACCCACAAGTCATTG; sgCXCR4-3, CAGGACAGGATGACAATACC) or human 420 
RGS14 gene (sgRGS14-1, GCAGGGATCTGTGAGAAACG; sgRGS14-2, 421 
TCGGCAGCCCTGACGCCACG; sgRGS14-3, CTGAGACTCTCGGCGCAAGG) were cloned 422 
into the vector lentiCRISPR-v2 (Addgene, #62961). 423 
Cell lines 424 
Jurkat cells (ATCC, Clone E6-1, TIB-152) were transduced with lentivirus expressing human 425 
CXCR1, CXCR3 or CXCR6, followed by treatment with 5 µg/ml blasticidin (CXCR1 and 426 
CXCR3) or 0.5 µg/ml puromycin (CXCR6) for two weeks, to generate Jurkat-CXCR4/CXCR1 427 
cells, Jurkat-CXCR4/CXCR3 cells and Jurkat-CXCR4/CXCR6 cells, respectively. For Raji B-428 
CXCR4/CXCR5 cells, Raji B cells (ATCC, CCL-86) were transduced with CXCR5 lentivirus 429 
followed by selection with 0.5 µg/ml puromycin for two weeks. Sub-population of CCRF-HSB-2 430 
cells (ATCC, CCL 120.1) that spontaneously express high level of CXCR3 were FACS sorted as 431 
HSB2DP-CXCR4/CXCR3 cells, where DP stands for “double positive”. The Molm13 cell line 432 
(Molm13-CXCR4/CCR2) which expresses both CXCR4 and CCR2 spontaneously was a gift 433 
from Dr. Vakoc’s laboratory. For CRISPR knock-outs, Jukat-CXCR4/CXCR3 and Molm13-434 
CXCR4/CCR2 cells were transduced with lentivirus expressing SpCas9 and control guide 435 
(sgScramble), guides targeting to CXCR4 (sgCXCR4) or RGS14 (sgRGS14). HSB2DP-436 
CXCR4/CXCR3 cells were cultured in IMDM medium (ATCC, 30-2005) supplemented with 437 
10% FBS (Seradigm, 1500-500), 100 units/ml penicillin and 100 µg/ml streptomycin. All the 438 
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other cell lines were cultured in RPMI-1640 medium (ATCC, 30-2001) plus 10% FBS and 439 
penicillin/streptomycin. Cells were maintained at the density of 1x105-1x106 cells/ml. 440 
Flow cytometry 441 
For each cell line, 1x105-1x106 cells were pellet and washed with cold FACS buffer (PBS, 2% 442 
FBS and 20 mM HEPES, pH 7.4), followed by Fc receptor blocking with Human TruStain FcX 443 
(BioLegend, 422301) in the FACS buffer at 4°C for 30 min. Cells were then stained with APC 444 
conjugated anti-Human CXCR4 antibody (BioLegend, 306510) and/or Alexa Fluor 488 445 
conjugated anti-Human CXCR1 antibody (BioLegend, 320616), PE conjugated anti-Human 446 
CXCR3 antibody (BioLegend, 353706), FITC conjugated anti-Human CCR2 antibody 447 
(BioLegend, 357215), FITC conjugated anti-Human CXCR5 antibody (BioLegend, 356913), 448 
APC conjugated anti-Human CXCR6 antibody (R & D Systems, FAB699A) for another 30 min 449 
at 4°C. Then, cells were washed with the FACS buffer twice and analyzed with BD LSRForsseta 450 
cell analyzer. 451 
Chemotaxis assays 452 
The chemotaxis buffer for HSB2DP-CXCR4/CXCR3 cells is IMDM medium plus 0.1% BSA 453 
and 20 mM HEPES, pH 7.5 and for all other cell lines is RPMI-1640 medium plus 0.1% BSA 454 
and 20 mM HEPES, pH 7.5. After collection, cells were washed for two times and re-suspended 455 
in the chemotaxis buffer at the density of 1x106/ml, followed by incubation at 37°C for 30 min. 456 
For the CXCL12 cross-inhibition of the other chemokine induced chemotaxis, 80 µl cells with or 457 
without 100 ng/ml (200 ng/ml for CCR2) recombinant human CXCL12 (R & D Systems, 350-458 
NS) were loaded in the upper wells of the Boyden chamber plate (VWR, 89089-934; Supplier 459 
NO. 3388, 5 µm membrane pore size), and the lower chambers were flowed in 240 µl 460 
chemotaxis buffer with PBS or the other specific recombinant human chemokine. To test the 461 
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effect of other specific chemokine on the CXCL12 induced chemotaxis, cells and the specific 462 
chemokine were loaded on the upper chamber, with CXCL12 containing chemotaxis buffer 463 
loaded in the lower chamber. To evaluate the activity of AMD3100 (Sigma, A5602) on CXCL12 464 
or the other specific chemokine induced chemotaxis, cells were pre-treated with increasing dose 465 
of the drug at 37°C for 30 min, then the cell/AMD3100 mixture was loaded in the upper 466 
chambers, and CXCL12 or other specific chemokine containing chemotaxis buffer was loaded in 467 
the lower chambers. For the AMD3100 rescue of the CXCL12 mediated cross-inhibition, the 468 
AMD3100 pre-treated cells together with 100 ng/ml CXCL12 were loaded in the upper 469 
chambers, and chemotaxis buffer containing the other specific chemokine was flowed in the 470 
lower chambers. After the experiments were set up, the Boyden chamber plates were incubated 471 
at 37°C for 2 or 3 hours. Then, the number of cells in the lower chamber was counted with a 472 
Guava bench-top flow cytometer, for 30 seconds at medium flow rate (~1.2 µl/s). The 473 
concentration of each chemokine used is as following: CXCL8 (R & D Systems, 208-IL), 20 474 
ng/ml; CXCL10 (R & D Systems, 266-IP), 1000 ng/ml; CXCL13 (R & D Systems, 801-CX), 475 
1000 ng/ml; CXCL16 (R & D Systems, 976-CX), 50 ng/ml; CCL2 (R & D Systems, 279-MC), 476 
200 ng/ml. 477 
RNA sequencing analysis 478 
Gene expression quantification and differential gene expression analysis 479 
Sequences of human transcripts were downloaded from Ensembl release 97. Transcripts 480 
quantification was performed using Kallisto ver. 0.43 and gene-level count matrices for use in 481 
DESeq2 were calculated using tximport as recommended by DESeq2 authors (46). All 482 
subsequent analyses on gene expression were performed using R 3.5.0. For differential 483 
expression analysis, raw counts were used directly in DESeq2. For other downstream analyses 484 
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(i.e. fold-change correlation plots) counts data were transformed using the variance stabilizing 485 
transformation (VST) as implemented in DESeq2. 486 
Gene set enrichment analysis (GSEA) 487 
Gene set enrichment analysis was performed using the fgsea package available in Bioconductor. 488 
GSEA plots were obtained using a modified version of the associated plotEnrichment function. 489 
All gene sets used in the manuscript are provided as supplementary table. Data used for Figure 490 
5A was obtained from several different sources: the rejecting allografts gene list was obtained 491 
from GEO series GSE48581 (29) and GSE36059 (28); the microsatellite instability gene list was 492 
obtained by combining Xena UCSC TCGA gene expression data (31) and MSI status for the 493 
same tumor samples (30); the list of genes associated with pan-cancer survival was obtained 494 
from the PRECOG portal (25); the anti-PD1 response gene lists were obtained from GEO: 495 
GSE91061 (32) and ENA: PRJEB23709 (33); the anti-CD20 gene list was obtained from Array 496 
Express: E-MTAB-7473 (34). 497 
Code availability 498 
The authors declare that the R code used to generate the analysis presented in this study is 499 
available upon reasonable request. 500 
 501 
Experimental medicine study 502 
Patient eligibility  503 
Patients with advanced or metastatic pancreatic adenocarcinoma (PDA), high grade serous 504 
ovarian cancer (HGSOC) or colorectal adenocarcinoma (CRC), refractory to or declining 505 
conventional chemotherapy were eligible for the dose escalation phase. The 10-patient expansion 506 
cohort at the recommended phase 2 dose (RP2D) of 80 µg/kg/hr was restricted to patients with 507 
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PDA. Other eligibility criteria included a lesion accessible to biopsy, Eastern Cooperative 508 
Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function including a 509 
lymphocyte count above the lower limit of normal. Patients were excluded if they had significant 510 
cardiac co-morbidities, such as past history of significant rhythm disturbance. Full eligibility 511 
criteria can be viewed at https://clinicaltrials.gov/ct2/show/NCT02179970. Patients were accrued 512 
at Cambridge University Hospitals NHS Foundation Trust and Weill Cornell Medicine/New 513 
York Presbyterian Hospital, NY, USA. 514 
Study design 515 
This phase 1, multicentre, open-label, non-randomized study used a 3+3 dose escalation design.  516 
The primary endpoint was the safety (evaluated using the Common Terminology Criteria for 517 
Adverse Events (CTCAE) 4.03) of AMD3100 administered, to achieve a plasma AMD3100 518 
concentration at steady state ≥2µg/ml in ≥ 80% of patients at the RP2D. AMD3100 was 519 
administered as a 7-day continuous infusion. Dose-limiting toxicity (DLT) was defined as an 520 
adverse reaction (AR) ≥G3 occurring within 21 days of AMD infusion. Secondary endpoints 521 
included overall response rate (RECIST 1.1) at 14 (+/-2) days after the infusion, and metabolic 522 
changes in tumor using [18F]FDG-PET/CT within 1 day of infusion completion. Baseline scans 523 
were performed within 14 days before the start of the infusion. Exploratory objectives included 524 
the assessment of immune changes in tumor biopsies.  Patients were monitored by cardiac 525 
telemetry for the initial 48hr of the infusion (later amended to 72hr), followed by Holter 526 
monitoring for the remainder of the infusion.  527 
Patients provided written informed consent to Research Ethics Committee-approved protocol 528 
(REC reference 15/EE/0014 at the UK center and IRB number 1508016466 at the US center), in 529 
compliance with Good Clinical Practice (GCP), local regulatory requirements and legal 530 
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requirements.  A Clinical Trial Authorisation (CTA) was obtained from the Medicine and 531 
Healthcare Regulatory Authority (MHRA). The study was sponsored by Cambridge University 532 
Hospitals NHS Foundation Trust and the University of Cambridge and Weill Cornell 533 
Medicine/New York Presbyterian Hospital.   534 
AMD3100 sample and pharmacokinetic analysis 535 
AMD3100 plasma concentration was assessed at the following nominal time points: pre-dose, 536 
24, 72 and 168 hrs of the infusion. A time point at day 7 (+/-2) after infusion discontinuation was 537 
added from patient 1017 onwards. The concentration data were generated using a liquid 538 
chromatography-tandem mass spectrometry (LC-MS/MS) method, that met the requirements of 539 
the EMA guidance on method validation, performed by the CRUK Cambridge Institute 540 
PK/Bioanalytics Core Facility. A claim of GCP compliance is made for the sample analysis data, 541 
pending the demonstration of long-term storage stability, which is on-going at the time of 542 
publication.  AMD3100 calibration standards were prepared in the range of 40-4,000 ng/mL 543 
using blank control human plasma obtained from the NHS blood transfusion service (lower limit 544 
of quantification (LLOQ) 40 ng/mL).  After the addition of the internal standard (AMD3100-D4) 545 
and EDTA (10mM), plasma samples, quality control (QC) and calibration standards were 546 
extracted by protein precipitation with 1% formic acid in methanol.  A portion of the supernatant 547 
was evaporated to dryness and the residue reconstituted in 1% formic acid in water prior to 548 
analysis on the LC-MS/MS.  High-performance liquid chromatography was performed with the 549 
Shimadzu Nexera X2 using a Phenomenex Kinetex F5 column (1.7µm, 100 x 2.1mm) and 550 
mobile phases A and B containing 0.1% formic acid in water or methanol, respectively.  MS/MS 551 
detection was carried out using a Sciex API6500 mass spectrometer with an electrospray source.  552 
QC samples (120, 400 and 3000 ng/mL) were used to determine the precision (coefficient of 553 
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variation [%CV]) and accuracy (relative error [%RE]).  QC intra-day %CV was ≤9.8%, and 554 
%RE ranged between -3.1 to 4.8%.  All instrument control and data collection was performed 555 
using Analyst v1.6.2, and peak area integration, regression and quantification using 556 
MultiQuant™ v3.0.2.  A weighted (1/x2) least square linear regression was used to construct the 557 
calibration line. 558 
 559 
Pharmacodynamic analysis 560 
At baseline, 24/72/168hr of the infusion, and 21(+/-2) days after infusion, blood was collected 561 
into Sarstedt EDTA blood tubes and CD34+ cells quantified by flow cytometry. The CD34+ 562 
absolute count was derived from a bead-based assay using BD Bioscience Trucount tubes and an 563 
ISHAGE gating strategy.  564 
 565 
Positron Emission Tomography 566 
Positron Emission Tomography (PET) was performed in conjunction with low dose Computed 567 
Tomography (CT) for attenuation correction and localization purposes. Images were acquired 568 
from the midbrain to the knees, approximately 90 (89.7 ± 21.1) min after the injection of ~370 569 
(368 ± 13) MBq of [18F]fluorodeoxyglucose ([18F]FDG). The baseline [18F]FDG-PET/CT was 570 
performed before or at least 24 hours after the core tissue biopsy, and the post treatment PET/CT 571 
was performed within 24 hours after the biopsy on day 8 of the study. 19 patients underwent 572 
imaging at both timepoints and were evaluated for metabolic changes following treatment. 573 
Response was determined by calculating the change in the mean weighted average of the 574 
Standardized Uptake Value (SUVMWA) of the [18F]FDG avid target lesions. SUVMWA was 575 
calculated as the sum of the product of the SUVmean75% and volume for all target lesions, 576 
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divided by the total target lesion volume. A clinically significant change was defined as change 577 
in SUVMWA ≥ 30%. 578 
 579 
Biopsy processing  580 
RNA and DNA extraction 581 
Snap frozen biopsies were embedded in chilled OCT (-4	℃) and allowed to solidify in a 582 
cryotome at -20	℃. Subsequently, ten 30µm sections were cut and collected in RLT buffer for 583 
DNA/RNA extraction, followed by six 6µm sections for histologic analysis. The remaining 584 
tissue was cut in 30µm sections until exhausted. All 30µm sections were extracted for DNA and 585 
RNA using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, 80224) according to 586 
manufacturer instructions from tissues, and DNA quantification by fluorometer according to 587 
manufacturer instructions (Qubit 3.0, Life technologies). An H&E was reviewed by a 588 
Histopathologist to determine cellular content (> 40% cancer cell content).  589 
 590 
Histopathologic analyses 591 
3 µm formalin-fixed, paraffin-embedded (FFPE) tissue sections were deparaffinised in xylene 592 
and rehydrated in an ethanol series. Immunofluorescence staining was performed on the Bond 593 
Rx automated platform. Sections were retrieved with Tris EDTA for 20 minutes and incubated 594 
sequentially with primary and secondary antibody pairs (where applicable) at room temperature 595 
for 30 minutes or, for CXCL12, 60 minutes. Slides were counterstained with DAPI and 596 
digitalized using the Axio Scan.Z1 (Zeiss) at 20 x (0.22µm/ pixel).  Tumour areas were selected 597 
based on review of serial H&E sections by a histopathologist: liver, peritoneal fat and necrosis 598 
were excluded.  The HighPlex FL v3.0.1 algorithm in Halo software (v2.3, Indica labs) was used 599 
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to automatically detect CD8 positive cells across all sections, with a tissue classifier that 600 
restricted analysis to pan-CK positive areas within the predefined tumour area.  The same 601 
algorithm was used for pre and post treatment biopsies. Cell counts were normalised to pan-CK 602 
tissue area (cells µm-2).  603 
Primary antibodies: CD8 (SP16; Lab Vision/Thermo Scientific), pan-cytokeratin (AE1/ AE3 604 
Alexa Fluor 488 conjugate; eBioscience), CXCL12 (79018; R&D). 605 
 606 
Immunological assays 607 
Fluorescent in-situ hybridization 608 
RNAscope (Advanced Cell Diagnostics, ACD) was performed following the standard protocol. 609 
Frozen sections were fixed with 4% paraformaldehyde (PFA) for 15 min at 4℃ and dehydrated 610 
with sequential ethanol solution (50%-100%) at room temperature. Sections were incubated with 611 
pretreat IV for 30 min and washed in phosphate-buffered saline before being hybridized with 612 
gene-specific probes (CCL19, FAP) for 2 h at 40℃ in a HybEZ oven. Sections were washed with 613 
wash buffer followed by incubations in sequential amplifers (Amp1-Amp4). Finally, sections 614 
were stained with DAPI and mounted with prolong antifade mountant. Images were taken by 615 
Leica SP8 confocal microscope and analyzed with ImageJ software. 616 
 617 
Plasma cell-free DNA analysis 618 
Blood samples were collected into EDTA-containing tubes and processed by a double-619 
centrifugation protocol (1,600 g for 10 minutes; 14,000 rpm for 10 minutes) before storage at -620 
80°C. Plasma DNA was extracted using QIAsymphony DSP Circulating DNA Kit (QIAGEN) and 621 
DNA sequencing libraries were prepared using the ThruPLEX Plasma-seq kit (Takara Bio). 622 
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Unique DNA barcode sequences were introduced to allow pooled sequencing runs on HiSeq 4000 623 
(Illumina) generating 150-bp long paired-end reads. Sequencing reads were subsequently aligned 624 
to the human reference genome (hg19) using BWA-mem. PCR and optical duplicates were marked 625 
using MarkDuplicates (Picard Tools) and excluded from downstream analysis along with reads of 626 
low mapping quality. Sequencing data in each sample were downsampled to 5 million reads to 627 
generate t-MAD scores (47) for estimating ctDNA levels inferred from a genome-wide copy 628 
number aberration profile. The segmentation step was summarized by a median value and a t-629 
MAD threshold of 0.015 was used.  630 
 631 
Cytokine analysis 632 
Serum was analysed for CXCL8 using the MesoScale Discovery Human 10-plex 633 
ProInflammatory Panel 1 kit (V-PLEX K15049D-2), as per manufacturer’s instructions. 634 
Analyses were conducted at the Core biochemical assay laboratory (CBAL) at CUH, NHS 635 
Foundation Trust. 636 
  637 
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Main figure legends 774 
Figure 1. The CXCL12-coat of human pancreatic and colorectal cancer cells. Sections of 775 
human pancreatic (PDA) and colorectal (CRC) adenocarcinoma were stained with fluorescent 776 
antibodies to CXCL12, and to KRT19 to reveal cancer cells. The ratios shown in the top right 777 
corners of the photomicrographs indicate the frequency of the observed staining relative to the 778 
total number of independent tumors that were assessed. Scale bar, 50 µm. 779 
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Figure 2. The effect of CXCL12-stimulated CXCR4 on chemokine receptor-mediated 781 
migration of human immune cells.  Left panels: The co-expression of CXCR4 with (A) 782 
CXCR1, (B) CXCR3, (C) CXCR5, (D) CXCR6, and (E) CCR2 on human immune cell lines was 783 
evaluated by flow cytometry after staining with antibodies specific for the relevant chemokine 784 
receptors. Gray peaks indicate isotype controls.  Middle panels: The effect of CXCL12-785 
stimulation of CXCR4 on the chemotactic responses of (A) CXCR1-co-expressing Jurkat T 786 
lymphoblastoid cells to CXCL8, (B) CXCR3-co-expressing HSB2DP T lymphoblastoid cells to 787 
CXCL10, (C) CXCR5-co-expressing Raji B lymphoblastoid cells to CXCL13, (D) CXCR6-co-788 
expressing Jurkat T lymphoblastoid cells to CXCL16, and (E) CCR2-co-expressing Molm13 789 
monocytoid cells to CCL2 was assessed by including CXCL12 in the upper chamber (blue) and 790 
the other chemokines in the lower chamber (red) in the Boyden two-chamber assay. Right 791 
panels: The chemotaxis assays were performed with the five cell lines when the placement of the 792 
chemokines in the Boyden chambers was reversed.  Bar diagrams display mean and standard 793 
error of the mean. Statistical analysis by student’s t test: ***, p<0.001; ****, p<0.0001; ns, not 794 
significant. 795 
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Figure 3. Inhibition by AMD3100 of the suppression mediated by CXCL12-stimulated 797 
CXCR4 of the function of other chemokine receptors. Panels A-E: The chemotactic 798 
responses were assessed of the dual chemokine receptor-expressing human immune cells to the 799 
relevant chemokines in the absence or presence of CXCL12, with increasing concentrations of 800 
AMD3100. The results are presented as percent of the chemotactic response in the absence of 801 
CXCL12 and AMD3100. The mean and standard error of the mean are indicated. 802 
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Figure 4. The immunological effects in human CRC and PDA of treatment with AMD3100. 804 
Paired biopsy tissues were obtained from the same metastasis in each patient before (pre-Rx) and 805 
after seven days of continuous infusion of AMD3100. (A) Tissue sections were stained with 806 
fluorescent antibodies to pan-keratin (pan-CK) to reveal cancer cells, and to CD8 to reveal 807 
cytotoxic T cells. White arrowheads designate CD8+ T cells within cancer cell islets, and red 808 
arrowheads designate CD8+ T cells outside of cancer cell islets. (B) The presence of CD8+ T 809 
cells within cancer cell islets, assessed by staining with anti-CD8 antibody, correlates with the 810 
CD8A mRNA levels, assessed by RNAseq analysis, in tissues obtained from different pass 811 
biopsies of the same metastatic lesions.  (C) Immunological gene sets that identify T and NK cell 812 
accumulation, T and NK cell effector cells, activated B cells (germinal center B cells) and 813 
plasma cells are enriched in genes upregulated after treatment with AMD3100. (D) The 814 
expression of CCL19 and FAP in sections from paired biopsies was analyzed by fluorescent in 815 
situ hybridization using specific probes for mRNA of FAP and CCL19. The total counts of 816 
FAP+/CCL19+ cells, FAP+/CCL19- cells, and FAP-/CCL19+ cells are displayed. (E) The 817 
enrichment analysis for a TLS gene set (13) is shown. (F and G) Enrichment analyses are shown 818 
for those genes that (F) are differentially expressed in rejecting compared to non-rejecting 819 
kidney allografts (28, 29) and (G) MSI compared to MSS CRC (30). (A-G) n=14 comprising of 820 
PDA (n=4) and CRC (n=10). Scale bar, 50 µm. Statistical comparisons by Spearman’s rank 821 
correlation test (B), and by Fisher’s exact test (D): ****, p<0.0001.  822 
 823 
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Figure 5. Comparative analyses of the integrated immune response (INTIRE) induced by 825 
AMD3100. (A) The heat map is shown of the enrichment analyses of nine gene sets representing 826 
different immune components that characterize the INTIRE in different immunological contexts, 827 
along with E2F target genes and genes involved in the G2M checkpoint. Comparative 828 
enrichment analyses for differentially expressed genes in paired biopsies with differential 829 
expressed genes from (B) biopsies from patients with longer versus shorter survival based on the 830 
PRECOG (25) analysis, (C) pre-treatment biopsies from patients with melanoma who responded 831 
to anti-PD1 treatment vs. non-responding patients (32,33), and (D) pre-treatment vs. week six of 832 
treatment biopsies from patients with melanoma who were depleted of B cell by treatment with 833 
anti-CD20 antibodies (34). (A-D) n=14 comprising of PDA (n=4) and CRC (n=10). 834 
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Figure 6. Analyses of the anti-cancer effect induced by AMD3100 treatment. (A) Changes of 836 
mRNA expression in the paired biopsies obtained from each patient with CRC (n=10) and with 837 
PDA (n=4) before and after treatment with AMD3100 for granzymes A, B, H, K, and M and 838 
perforin negatively correlate with changes in the expression of CEACAM 5,6, and 7. (B) Plasma 839 
ctDNA levels (n=15) and (C) serum concentrations of CXCL8 (n=18) pre-treatment (pre-Rx) 840 
and after seven days of continuous infusion of AMD3100 are shown. Statistical comparisons by 841 
Spearman’s rank correlation test (A), by paired Wilcoxon signed-rank test paired (B), and by 842 
paired t-test (C): *, p<0.05; ****, p<0.0001.   843 
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Supplementary figure legends 844 
 845 
Figure S1. The inhibition by CXCL12 of CXCR3- and CCR2-mediated chemotaxis of 846 
human immune cells depends on CXCR4 co-expression.  (A) Jurkat-CXCR4/CXCR3 T 847 
lymphoblastoid cells were CRISPR/Cas9-edited with different sgRNAs and assessed for CXCR4 848 
expression by FACS analysis, chemotaxis to CXCL12 in the lower Boyden chamber, and 849 
chemotaxis to CXCL10 in the lower chamber in the presence of CXCL12 in the upper chamber.  850 
(B) Molm13-CXCR4/CCR2 monocytoid cells were CRISPR/Cas9-edited with different sgRNAs 851 
and assessed for CXCR4 expression by FACS analysis, chemotaxis to CXCL12 in the lower 852 
Boyden chamber, and chemotaxis to CCL2 in the lower chamber in the presence of CXCL12 in 853 
the upper chamber. Statistical analysis by student’s t test: ***, p<0.001; ****, p<0.0001. 854 
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Figure S2. The reversibility of inhibition by CXCL12 of CXCL10-induced chemotaxis.  856 
HSB2DP-CXCR4/CXCR3 T lymphoblastoid cells were treated with PBS (Ctrl) or CXCL12 at 857 
37°C for 15 minutes, followed by washing and resuspension in culture medium. After resting at 858 
37°C for timed intervals, the cells were assessed for their chemotactic responses to CXCL12 859 
(blue bars) or CXCL10 (red bars).  860 
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Figure S3. The effect of AMD3100 on the directed migration of the dual chemokine 862 
receptor-expressing human cells.  The chemotactic responses of (A) Jurkat-CXCR4/CXCR1 863 
cells, (B) HSB2DP-CXCR4/CXCR3 cells, (C) Raji B-CXCR4/CXCR5 cells, (D) Jurkat-864 
CXCR4/CXCR6 cells, and (E) Molm13-CXCR4/CCR2 cells was assessed in the presence of the 865 
indicated chemokines and increasing concentrations of AMD3100.  The results are expressed as 866 
percentage of the responses occurring in the absence of AMD3100. 867 
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Figure S4. Consort diagram of the experimental medicine study (NCT02179970). 869 
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Figure S5. Schematic of the experimental medicine study and the pharmacokinetic and 871 
toxicity results. (A) The study time line is shown for the experimental medicine study of 872 
continuous iv infusion of AMD3100 to patients with PDA and CRC. (B) Plasma concentrations 873 
of AMD3100 at increasing dose levels of the iv infusion on day 2, 4, and 8 of the study are 874 
displayed. The mean and standard error of the mean are indicated.  875 
  876 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2020. ; https://doi.org/10.1101/2020.07.08.20129361doi: medRxiv preprint 
 48 
Figure S6. The CXCL12-coat on pancreatic and colorectal cancer cells from biopsies of 877 
study patients. For patients enrolled during the dose escalation part of the study, sections of 878 
biopsies of metastases from patients with pancreatic (PDA) and colorectal (CRC) 879 
adenocarcinoma were stained with fluorescent antibodies to pan-CK to reveal cancer cells, and to 880 
CXCL12. The ratios shown in the top right corners of the photomicrographs indicate the 881 
frequency of the observed staining relative to the total number of independent tumors assessed. 882 
Scale bar, 50 µm. 883 
 884 
  885 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2020. ; https://doi.org/10.1101/2020.07.08.20129361doi: medRxiv preprint 
 49 
Figure S7. The effect of continuous AMD3100 administration on peripheral blood 886 
leukocyte levels. The relative levels for six leukocyte subtypes on study day two, four, eight, and 887 
28, as compared to the levels of day one, are displayed. Subdivisions by dose level of AMD3100 888 
are included for each study day. Statistical comparison of study day levels by nested ANOVA: *, 889 
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; ns, not significant. 890 
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Figure S8. Quantification of immunehistochemical and transcriptional analyses of the 892 
frequency of intratumoral CD8+ T cells.  Paired biopsies of metastases obtained from each 893 
patient with CRC or PDA were analyzed. (A) The frequency of CD8+ T cells, assessed by 894 
immunofluorescent staining of FFPE tissue, within cancer cell islets is displayed. (B) The 895 
mRNA levels of CD8A, assessed by RNAseq analysis, are shown. (A and B) n=14 comprising of 896 
PDA (n=4) and CRC (n=10). Statistical comparisons by paired t-test (A), and by Wald test (B): 897 
*, p<0.05; ****, p<0.0001.   898 
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Figure S9. Correlation of granzymes and perforin with the expression of non-cancer-899 
specific genes after AMD3100 treatment.  Changes of mRNA expression after AMD3100 900 
administration for granzymes A, B, H, K, and M and perforin compared to changes in mRNA 901 
expression for (A) EEF1A1, (B) ACTB, and (C) RPLP0 are shown. Statistical comparisons by 902 
Spearman’s rank correlation test are shown. 903 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 10, 2020. ; https://doi.org/10.1101/2020.07.08.20129361doi: medRxiv preprint 
Table 1.  Patient Characteristics  
Characteristic N=26 
Age - yr   
      Mean 66 
      Range 50-76 
Female sex – no (%) 9 (35) 
Histology - no. (%)   
      Pancreatic adenocarcinoma 10 (38) 
      Colorectal adenocarcinoma 15 (58) 
      Neuroendocrine  cancer¶                  1 (4) 
ECOG - no. (%)   
       0 9 (35) 
       1 17 (65) 
Lymphocyte count (109/L)   
       Median 1.41 
       Range* 0.82-2.31 
Albumin < 35 g/L - no. (%) 13 (50) 
Sites of metastasis >2 - no. (%) 16 (62) 
Prior lines of chemotherapy- no. 
(%)   
       0  1(4) 
       1  1(4) 
       2 16 (62) 
       ≥3   8 (31) 
¶ On central review of research biopsies, pathology consistent with neuroendocrine 
pancreatic cancer, excluded from later analysis 
*1 patient had a low count at enrolment that normalized on day 1 pre-infusion  
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Figure 2 Figure 2
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Figure 4
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Figure 6









































































A CR = -0.91; p-value = 4.7e-06
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Adverse event Relation to plerixafor Action Outcome of adverse event
40 1007 7 Biliary tract obstruction and infection Unlikely to be related Discontinued Recovered
120 1013 5 Duodenal obstruction Unlikely to be related Discontinued Recovered
120 1014 8 Vasovagal reaction* Possibly related Discontinued Recovered
120 1018 2 Vasovagal reaction, hypotension, abdominal pain* Possibly related Discontinued Recovered
80 1022 4 Panic attack Possibly related Discontinued Recovered
* Dose Limiting Toxicity
Supplemental Tables and Figures
Biasci et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated 
immune response
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Table S2. Drug related adverse events during dose escalation and expansion phase
Category Term 01 02 03 04 05 07 08 09 10 11 12 13 14 15 16 17 18 G1-2 (n (%)) G3-4 (n (%))
Atrial fibrilation 1 (9) 0
Multifocal atrial tachycardia 1 (9) 0
Palpitations 1 (9) 0
Supraventricular ectopic beats 1 1
Supraventricular tachycardia 1 2 (18) 0
Ventricular arrhythmia 1 1 (9)
Eye Watering eyes 1
Abdominal pain 1 1 2 1 3 4 (36) 0
Abdominal distention 2
Diarrhea 1 1 1 2 1 1 1 1 1 2 8 (73) 0
Dry mouth 1 1
Flatulence 1 1 1 (9) 0
Nausea 1 1 1 1 1 1 4 (36) 0
Vomiting 1 2 1 1 (9) 0
Chills 1
Fatigue 2 1 (9) 0
Fever 2 2 (18) 0
Non-cardiac chest pain 1 (9) 0
Anemia 2 0 1 (9)
Platelet count decreased 1 1 2 (18) 0
Infections Oral candidiasis 1 (9) 0
ALK Phosphatase increased 1 1 1 1 (9) 0
ALT increased 1 2 2 1 1 2 (18) 0
Creatinine increased 1
INR increased 1
Anorexia 2 2 2 (18) 0
Hypoalbuminemia 2 1 1 1 1 2 1 2 2 5 (45) 0
Hypoglycemia 1
Hypokalemia 1 1 (9) 0
Hypophosphatemia 1 2
Abnormal dreams 1 1 1 3 (27) 0
Dizziness 1 1 (9) 0
Dysgeusia 1 1 1 (9) 0
Headache 1 1 1
Paresthesia 1 1 2 1 2 1 1 1 1 2 8 (73) 0
Presyncope 1 (9) 0
Tremor 1
Vasovagal reaction 3 3
Renal Proteinuria 1 1 1 2 1 (9) 0
Dyspnea 1 1 (9) 0
Rhinorrhea 1
Anxiety 1 1 (9) 0
Claustrophobia 1
Confusion 1 (9) 0
Insomnia 2 2 1 1 1 2 1 1 1 2 1 2 1 2 6 (55) 0
Panic attack 0 1 (9)
Hot flashes/flushing 1 1 1 1 1 1 1 4 (36) 0
Hypertension 0 1 (9)
Hypotension 3 1 (9) 0
Adverse event grade 1 2 3
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Css                               
(µg/ml) 
AUC0-168                         
(µg*h/ml) 
Cl                          
(L/hr) 
20 3* 0.58 (0.57-0.60) 76 (72-80) 2.86 (2.64-3.10) 
40 4* 1.05 (0.74-1.32) 143 (110-174) 2.76 (2.67-2.92) 
80 11# 2.28 (1.17-3.80) 324 (182-544) 2.82 (1.90-3.53) 
120 7† 2.99 (2.38-4.16) 431 (359-570) 3.14 (2.45-3.74) 
Mean (range)     
* Patient 1007 withdrawn at day 6, excluded   
# Patient 1022 withdrawn at day 4, excluded   
† Patients 1013, 1014 and 1018 withdrawn at day 5, 8, and 2, respectively, 
excluded.   
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Figure S2Supplementary Fig. 3
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Assessed for eligibility and 
consented (n= 34)        
Excluded (n= 8) 
• 8 did not meet eligibility criteria 
  
Registered (n= 26) 
Enrollment 
Lost to follow-up  (n= 0) 
Discontinued intervention due to toxicities (n= 6)  
Dose escalation phase (n= 18) 
• 13 completed the treatment 
• 4 stopped treatment early due to; 
o SAE (n= 2) 
o DLT (n= 2) 
• 1 did not receive any intervention and was 
withdrawn prior to treatment 
commencement due to a SAE 
Treatment Expansion phase (n= 8) 
• 7 completed the trial 
• 1 stopped treatment early due to a SAE 
Follow-Up 
Treatment 
Analysed (n= 25)  
1/26 patient did not receive study drug 
Safety and PK  
Analysis 
Plasma analysis of 
circulating tumor DNA (n=15) 
and serum analysis of CXCL8 
(n=18) 
Radiological analysis 
CT (n=23, day 20 to24 vs. pre-Rx) 




FFPE, and frozen tissue analysis (n=14, pre-Rx vs. 
day 8) 
7/25 patients did not undergo a 2nd biopsy  
2/25 patient samples with insufficient RNA quality 
1/25 no cancer tissue in biopsies 
1/25 patient with predominantly neuro-endocrine 
tumour on central pathology review 
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Biopsy 1 (Pre-Rx ), Plasma tumor markers Biopsy 2 (AMD3100), Plasma tumor markers
AMD3100 iv
continuous administrationScreening
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Figure S7
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Figure S9
Granzymes and perforin fold-change 
after AMD3100 (log2)
















































R = -0.26; p-value = 0.38
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